Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Adverum Biotechnologies ( (ADVM) ) just unveiled an update.
Adverum Biotechnologies reported encouraging results from its LUNA Phase 2 and OPTIC extension trials, showcasing its promising gene therapy candidate, Ixo-vec, for treating wet age-related macular degeneration (AMD). The trials demonstrated significant reductions in anti-VEGF injection burdens and maintained visual and anatomical outcomes, highlighting Ixo-vec’s potential to transform the treatment landscape for wet AMD. With robust patient preference and a favorable safety profile, Ixo-vec is poised for further clinical success as it progresses towards Phase 3 trials.
See more data about ADVM stock on TipRanks’ Stock Analysis page.
Trending Articles
- Boeing (NYSE:BA) Layoffs Expand, Start Hitting Multiple Factories
- Microsoft’s (NASDAQ:MSFT) New Computer is Exclusively a Cloud Machine
- Walmart (NYSE:WMT) Warns About Tariff-Driven Price Hikes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
